IAP-0971

N/A

Report date: 2025/11/25 12:16:34

Base Information

Drug NameIAP-0971
Drug Alias NameIAP-0971
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionProgrammed cell death protein 1 blockersInterleukin-15 receptors agonists
TargetsProgrammed cell death protein 1Interleukin-15 receptors
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell Lung +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSunHo (China) BioPharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSunHo (China) BioPharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell Lung +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A